WO2005095447A3 - Low molecular weight forms of foxp1 proteins and splice variants thereof - Google Patents

Low molecular weight forms of foxp1 proteins and splice variants thereof Download PDF

Info

Publication number
WO2005095447A3
WO2005095447A3 PCT/GB2005/001149 GB2005001149W WO2005095447A3 WO 2005095447 A3 WO2005095447 A3 WO 2005095447A3 GB 2005001149 W GB2005001149 W GB 2005001149W WO 2005095447 A3 WO2005095447 A3 WO 2005095447A3
Authority
WO
WIPO (PCT)
Prior art keywords
foxp1
splice variant
molecular weight
low molecular
weight forms
Prior art date
Application number
PCT/GB2005/001149
Other languages
French (fr)
Other versions
WO2005095447A2 (en
Inventor
Alison Banham
Sally Ashe
Phillip J Brown
Original Assignee
Isis Innovation
Alison Banham
Sally Ashe
Phillip J Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407039A external-priority patent/GB0407039D0/en
Priority claimed from GB0425554A external-priority patent/GB0425554D0/en
Application filed by Isis Innovation, Alison Banham, Sally Ashe, Phillip J Brown filed Critical Isis Innovation
Publication of WO2005095447A2 publication Critical patent/WO2005095447A2/en
Publication of WO2005095447A3 publication Critical patent/WO2005095447A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is based on the discovery that low molecular weight forms of the FOXP1 protein are expressed at high levels in activated B-cells and in a certain subtype of diffuse large B-cell lymphoma (DLBCL). The invention relates to a novel FOXP1 splice variant, the protein encoded by the splice variant and methods of detection and diagnosis based upon detecting the novel splice variant. Also provided are reagents including siRNA molecules which can down regulate the transcript of the splice variant, as well as methods of treatment of diseases associated with an activated B-cell state and pharmaceutical compositions.
PCT/GB2005/001149 2004-03-29 2005-03-29 Low molecular weight forms of foxp1 proteins and splice variants thereof WO2005095447A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407039A GB0407039D0 (en) 2004-03-29 2004-03-29 New FOXP1 proteins
GB0407039.7 2004-03-29
GB0425554A GB0425554D0 (en) 2004-11-19 2004-11-19 New foxp1 proteins
GB0425554.3 2004-11-19

Publications (2)

Publication Number Publication Date
WO2005095447A2 WO2005095447A2 (en) 2005-10-13
WO2005095447A3 true WO2005095447A3 (en) 2005-12-22

Family

ID=35063289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/001149 WO2005095447A2 (en) 2004-03-29 2005-03-29 Low molecular weight forms of foxp1 proteins and splice variants thereof

Country Status (1)

Country Link
WO (1) WO2005095447A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063019A1 (en) * 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040303A1 (en) * 1999-12-02 2001-06-07 Isis Innovation Limited Transcription factors containing two potential dna binding motifs
WO2004022103A2 (en) * 2002-09-06 2004-03-18 Isis Innovation Ltd. Foxp1 and uses thereof
WO2004058805A2 (en) * 2002-12-26 2004-07-15 Asahi Kasei Pharma Corporation T cell activating gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040303A1 (en) * 1999-12-02 2001-06-07 Isis Innovation Limited Transcription factors containing two potential dna binding motifs
WO2004022103A2 (en) * 2002-09-06 2004-03-18 Isis Innovation Ltd. Foxp1 and uses thereof
WO2004058805A2 (en) * 2002-12-26 2004-07-15 Asahi Kasei Pharma Corporation T cell activating gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANHAM A H ET AL: "The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 24, 15 December 2001 (2001-12-15), pages 8820 - 8829, XP002264689, ISSN: 0008-5472 *
BANHAM ALISON H ET AL: "Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 FEB 2005, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1065 - 1072, XP002350589, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2005095447A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
WO2005087953A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
EP2423327A3 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
WO2007098184A3 (en) Methods and compositions for analyte detection
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
WO2009151691A3 (en) Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
WO2008033239A8 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2001042504A3 (en) Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
WO2007050705A3 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2004081186A3 (en) Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
WO2003084388A3 (en) Early detection of sepsis
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2005110109A3 (en) Colorimetric and fluorometric determination of homocysteine and cysteine
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
WO2006110594A3 (en) Sema4d in cancer diagnosis, detection and treatment
DK2332582T3 (en) ACE2 activation for the treatment of heart, lung and kidney diseases and high blood pressure
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2006054297A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2007142763A8 (en) Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2005014797A3 (en) P16 mediated regulation of nmda receptors
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
WO2008081938A1 (en) Use of thermostable biotin-binding protein and solid support having the protein bound thereto
WO2008051511A3 (en) Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase